Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | TNF-a | 100 | ng/mL | 1 | MMP-2 | 556.0 | 27 | ||||
N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MMP-2 | 210.0 | 42 | |
N2759 | TNF-a | 100 | ng/mL | 1 | MMP-2 | 398.0 | 37 | ||||
RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MMP-2 | 199.0 | 35 | |
RA1931 | TNF-a | 100 | ng/mL | 1 | MMP-2 | 207.5 | 18 | ||||
N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | MMP-2 | 304.0 | 50 | |
N2586 | TNF-a | 100 | ng/mL | 1 | MMP-2 | 356.0 | 44 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 363.0 | 31 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 592.0 | 19 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 484.0 | 42 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 454.0 | 35 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 229.0 | 37 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 151.5 | 40 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 634.5 | 38 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 279.0 | 39 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 305.0 | 36 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 649.0 | 41 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 253.0 | 27 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 517.0 | 27 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 199.0 | 41 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 327.0 | 28 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 459.0 | 21 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MMP-2 | 358.0 | 43 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-2 | 424.0 | 37 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-2 | 471.0 | 31 |